Tubulis Secures $361 Million Series C to Advance Clinical-Stage Antibody-Drug Conjugates (ADCs)

Tubulis, a German biotech company specializing in antibody-drug conjugates (ADCs), raised $361 million in Series C funding led by Venrock, with participation from several global biotech investors1 5.

The new capital will accelerate clinical development of Tubulis's lead ADC candidate, TUB-040, which targets NaPi2b in ovarian and lung cancers, with plans to expand trials into additional tumor types and earlier lines of therapy5.

Funding also supports advancement of a second ADC candidate, TUB-030, targeting the 5T4 antigen found across various solid tumors5.

Tubulis leverages its proprietary P5 conjugation platform and the Tubutecan platform to create ADCs with high drug-to-antibody ratios and reduced off-target toxicity, aiming to set a new standard for potency and safety in the field5.

The company has strategic partnerships with pharmaceutical giants Bristol Myers Squibb (BMS) and Gilead, which validate Tubulis's technology and include milestone payments and licensing agreements5 7 10.

Investment will expand Tubulis's R&D and commercial infrastructure, particularly in the U.S., and strengthen its position in the fast-growing, $15B global ADC market5.

This Series C marks a continuation of Tubulis’s rapid funding trajectory, following a €128 million Series B2 round in March 2024, reflecting strong investor confidence in its clinical and technological strategy1 3 11.